Page 95 - Haematologica3

CD36 defines CML cells less sensitive to imatinib
research funding from Bristol-Myers Squibb and Pfizer, respective- ly. In addition, we wish to thank Linda Magnusson for critical experimental assistance.
Funding
This work was supported by the Swedish Cancer Society, the
Swedish Children’s Cancer Foundation, the Medical Faculty of Lund University, the Swedish Research Council, BioCARE, and the ISREC Foundation by a joint grant to Swiss Cancer Center, Lausanne, CREATE Health Cancer Center, and the Medical Faculty of Lund University from the Biltema Foundation. SM is supported by the Finnish Cancer Institute.
References
1. Ren R. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172- 183.
2. Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017; 129(12):1595-1606
3. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872- 884.
4. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014 Jan 16;20(2):310-322.
5. Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8):1638-1647.
6. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multi- ple unique features of resistance to BCR- ABL targeted therapies. Leukemia. 2007; 21(5):926-935.
7. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011; 121(1):396-409.
8. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012; 119(6):1501- 1510.
9. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657-3660.
10. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodefi- cient mice and produce a model of the human disease. Leukemia. 2005;19(3):435- 441.
11. Jaras M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010; 107(37):16280-16285.
12. Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014; 123(25):3951-3962.
13. Landberg N, Hansen N, Askmyr M, et al. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy out- come. Leukemia. 2015;30(1):253-257.
14. Warfvinge R, Geironson Ulfsson L,
Sommarin MNE, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopula- tions in CML. Blood. 2017;129(17):2384- 2394.
15. Mustjoki S, Richter J, Barbany G, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chron- ic myeloid leukemia patients. Leukemia. 2013;27(7):1520-1526.
mediate cell killing in xenograft models.
Blood. 2016;128(23):2683–2693.
28. Sadovnik I, Hoelbl-Kovacic A, Herrmann H, et al. Identification of CD25 as dependent growth-regulator of leukemic stem cells.
Clin Cancer Res. 2016;22(8):2051-2061.
29. Miller PG, Al-Shahrour F, Hartwell KA, et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013; 24(1):45-
16. Hjorth-Hansen H, Stenke L, Söderlund S, et 58.
al. Dasatinib induces fast and deep respons- es in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2014;94(3):243-250.
17. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
18. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differenti- ation. Nat Biotechnol. 2010;28(5):511-515.
19. Janssen JJWM, Deenik W, Smolders KGM, et al. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia. 2011;26(5):977-984.
20. Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL- rearranged acute myeloid leukemia. Cell Stem Cell. 2015;17(4):412-421.
21. Kinstrie R, Horne GA, Morrison H, et al. CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia. Blood. 2015;126(23):49.
22. Tartaglia LA. The Leptin Receptor. J Biol Chem. 1997;272(10):6093-6096.
23. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112(13):4793–4807.
24. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of CD34+ hematopoi- etic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21(3):494-504.
25. Gerber JM, Gucwa JL, Esopi D, et al. Genome-wide comparison of the transcrip- tomes of highly enriched normal and chron- ic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013; 4(5):715- 728.
30. Liu Q, Wang M, Hu Y, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leuk Lymphoma. 2014;55(4):892-898.
31. Silverstein RL, Febbraio M. CD36, a scav- enger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2(72):re3.
32. Harb D, Bujold K, Febbraio M, Sirois MG, Ong H, Marleau S. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc Res. 2009;83(1):42-51.
33. Ye H, Adane B, Khan N, et al. Leukemic stem cells evade chemotherapy by metabol- ic adaptation to an adipose tissue niche. Cell Stem Cell. 2016;19(1):23-37.
34. Pascual G, Avgustinova A, Mejetta S, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2016;541(7635):41-45.
35. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and patho- physiology. Am J Physiol Endocrinol Metab. 2011;301(4):E567-84.
36. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491-495.
37. Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR, Matthews W. A role for leptin and its cognate receptor in hematopoiesis. Curr Biol. 1996;6(9):1170-1180.
38. Feldmana DE, Chena C, Punjb V, Hidekazu Tsukamotoc DE, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci USA. 2012;109(3):829-834.
39. Yue R, Zhou BO, Shimada IS, Zhao Z, Morrison SJ. Leptin receptor promotes adi- pogenesis and reduces osteogenesis by reg- ulating mesenchymal stromal cells in adult bone marrow. Cell Stem Cell. 2016; 18(6):782-796.
40. Uddin S, Mohammad RM. Role of leptin and leptin receptors in hematological malig- nancies. Leuk Lymphoma. 2016; 57(1):10-
26. Majeti R. Monoclonal antibody therapy
directed against human acute myeloid
leukemia stem cells. Oncogene. 2010; 16.
30(9):1009-1019.
27. Ågerstam H, Hansen N, Palffy von S, et al.
IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and
41. Ozturk K, Avcu F, Ural AU. Aberrant expres- sions of leptin and adiponectin receptor iso- forms in chronic myeloid leukemia patients. Cytokine. 2012; 57(1):61-67.
haematologica | 2018; 103(3)
455